Staff editor
The first-in-human study double-blind, placebo controlled, 28-day crossover study of the safety and tolerability of SB-121
Gabriel Leventhal, Chief Scientific Officer at Pharmabiome, spoke about NicheMap, a reference database that allows us to select the most appropriate strains to engineer targeted changes in the microbiome.
Healthcare professionals area, Scientific research
Sponsored by
Download the review that summarize the scientific and clinical work conducted on the probiotic formulation Probi® Osteo.
Colette Shortt, Regulatory Specialist and Visiting Professor University of Ulster, spoke about the regulatory framework for food supplements and Live Biotherapeutic products.
Hepatic encephalopathy is a debilitating and recurring condition that causes neuropsychiatric conditions and is a common complication of cirrhosis.
Shahram Lavasani, Founder & CEO at ImmuneBiotech AB, spoke about how the research in gut-brain axes could pave the way to new microbiome based therapies in neurodegenerative diseases.
Industry
Sponsored by
Bio-Me launching an extensive qPCR solution for skin microbiome analysis.
Oliver Worsley: ‘The collaboration will give us the opportunity to further understand how molecular changes on the skin may translate to skin and human health’.
Tim Sharpington, Chief Executive Officer at Microbiotica, talked about how the microbiome field should navigate through a difficult financing horizon.
New study shows that specific probiotics significantly contribute to the modulation of mood and sleep quality during stressful periods.
